Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.2253
Abstract: Key Points Question Does the addition of apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, to treatment with pegylated liposomal doxorubicin (PLD) improve progression-free survival in patients with platinum-resistant recurrent ovarian cancer?… read more here.
Keywords: pegylated liposomal; recurrent ovarian; platinum resistant; liposomal doxorubicin ... See more keywords
Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5705
Abstract: The objective of this study was to evaluate the efficacy of gemcitabine plus nab‐paclitaxel in patients with recurrent ovarian cancer. read more here.
Keywords: recurrent ovarian; ovarian cancer; efficacy gemcitabine; gemcitabine combination ... See more keywords
Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27125
Abstract: The aim of this study is to evaluate the progression‐free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). read more here.
Keywords: intraperitoneal chemotherapy; ovarian cancer; hyperthermic intraperitoneal; recurrent ovarian ... See more keywords
Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213
Sign Up to like & getrecommendations! Published in 2019 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-019-04778-1
Abstract: Background The aim of this study was to analyze the potential impact of chemotherapy-induced nausea and vomiting (CINV) on dose reductions, discontinuation of chemotherapy, and survival. Patients and methods This study was designed as individual… read more here.
Keywords: chemotherapy; grade iii; ovarian cancer; recurrent ovarian ... See more keywords
Recurrent Ovarian Torsion and Fixation – Risk Factors and Predictors for Treatment Outcome
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Minimally Invasive Gynecology"
DOI: 10.1016/j.jmig.2021.09.493
Abstract: Study Objective Identifying risk factors for recurrent ovarian torsion and evaluation of the efficacy of ovarian fixation techniques. Design Retrospective cohort study. Setting Tertiary-care medical center. Patients or Participants Seventy-nine women with recurrent ovarian torsion… read more here.
Keywords: fixation; torsion; risk factors; ovarian torsion ... See more keywords
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.10.003
Abstract: PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair pathway, namely BRCA1/2 mutations. Given the limited therapeutic options for… read more here.
Keywords: parp inhibitors; inhibitors clinical; parp; resistance ... See more keywords
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.10.007
Abstract: OBJECTIVES The objective of this study was to determine the overall tolerability and toxicity of olaparib capsules among older (≥65years) patients with recurrent ovarian cancer treated on 8 completed prospective trials of olaparib. METHODS An… read more here.
Keywords: olaparib capsules; age; toxicity; ovarian cancer ... See more keywords
Trends in actionable mutations for recurrent ovarian and endometrial cancer at a single institution
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)01249-x
Abstract: Objectives: To identify actionable gene mutations in recurrent ovarian and endometrial cancer and to evaluate the effect of these cancer specific mutations on survival outcomes at a single institution. Methods: This was an institutional review… read more here.
Keywords: mutations recurrent; endometrial cancer; recurrent ovarian; cancer ... See more keywords
A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01098-8
Abstract: Background This Phase 2b study compared the efficacy and toxicity of belotecan and topotecan in recurrent ovarian cancer. Methods Patients with platinum-sensitive recurrent or platinum-resistant recurrent ovarian cancer (PRROC) were randomised 1:1 to receive belotecan… read more here.
Keywords: belotecan topotecan; ovarian cancer; recurrent ovarian; cancer ... See more keywords
Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-88382-6
Abstract: Erythropoietin producing hepatocellular (Eph) receptors and their membrane-bound ligands ephrins are variably expressed in epithelial cancers, with context-dependent implications to both tumor-promoting and -suppressive processes in ways that remain incompletely understood. Using ovarian cancer tissue… read more here.
Keywords: epha2; aggressive recurrent; ovarian cancers; recurrent ovarian ... See more keywords
Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13806
Abstract: Apatinib, an oral antiangiogenic drug, exerts potential anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to paclitaxel monotherapy in PROC patients. read more here.
Keywords: recurrent ovarian; platinum resistant; ovarian cancer; apatinib plus ... See more keywords